KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $500000.0.

  • Supernus Pharmaceuticals' Accumulated Depreciation & Amortization fell 1666.67% to $500000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500000.0, marking a year-over-year decrease of 1666.67%. This contributed to the annual value of $80.4 million for FY2024, which is 523.81% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Accumulated Depreciation & Amortization of $500000.0 as of Q3 2025, which was down 1666.67% from $500000.0 recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $85.5 million for Q4 2022, and its period low was $500000.0 during Q2 2025.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $800000.0 (2022), whereas its average is $20.0 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Accumulated Depreciation & Amortization surged by 121840.0% in 2021 and then tumbled by 2500.0% in 2023.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $32.6 million in 2021, then skyrocketed by 162.44% to $85.5 million in 2022, then decreased by 0.8% to $84.9 million in 2023, then fell by 5.24% to $80.4 million in 2024, then plummeted by 99.38% to $500000.0 in 2025.
  • Its Accumulated Depreciation & Amortization stands at $500000.0 for Q3 2025, versus $500000.0 for Q2 2025 and $20.4 million for Q1 2025.